Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful hard but unsuccessfully to produce a single therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the healing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the last few shares of mine. The 1st CytoDyn article of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such a very marketing image in the Uptick Newswire job interview that I came away with a poor opinion of the company.

Irony of irony, the bad opinion of mine of the company has grown steadily, though the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this expertise as well as connected intellectual property from Progenics to CytoDyn, and roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) and also the very first brand new drug program endorsement ($five million), as well as royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous therapies and many indications, it’s this individual remedy and a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy of dozens of indications.

The opening banner of its on its site (below) shows an active business with diverse interests albeit centered on leronlimab, multiple illness sorts, multiple presentations in addition to multiple publications.

Can all this be smoke and mirrors? That is a question I have been asking myself through the very start of the interest of mine in this particular company. Judging by way of the multiples of thousands of various remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m much from alone in this question.

CytoDyn is a classic battleground, or possibly some could say cult stock. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *